GLP-1 coverage in New Brunswick

New Brunswick Drug Plans is an umbrella term for several programs rather than a single plan, including an income-tested plan for residents without private drug insurance and separate coverage for people receiving income assistance. Eligibility and cost-sharing depend on which specific plan a resident qualifies for.

GLP-1 medications such as Ozempic can be covered under these plans when prescribed for type 2 diabetes and approved through New Brunswick's Special Authorization process for restricted drugs, which requires a prescriber to submit documentation showing the patient meets specific clinical criteria.

Special Authorization approval for semaglutide and tirzepatide products in New Brunswick is built around the diabetes indication. A prescription for Wegovy, Saxenda, or an off-label weight-loss use of a diabetes-approved GLP-1 doesn't meet that criteria and isn't reimbursed under any New Brunswick Drug Plan.

This mirrors every other provincial plan in Canada: none currently covers a GLP-1 prescribed specifically for weight management. Because Special Authorization criteria are reviewed over time, confirm current rules directly with New Brunswick's drug plan administrator.

New Brunswickers without applicable coverage will generally find Costco Pharmacy the least expensive dispensing option nationally, with no membership required at the pharmacy counter. Generic semaglutide, available since the May 2026 launch by Apotex and Dr. Reddy's, runs roughly $88 to $99/mo nationally; New Brunswick-specific Costco pricing isn't independently verified here.

Brand-name pricing at retail pharmacies runs higher: Ozempic $250-$310/mo, Wegovy $400-$570/mo, Mounjaro $280-$550/mo, Zepbound $435-$550/mo. About 31% of employer private plans now cover GLP-1s for weight loss, and manufacturer savings cards can reduce brand costs, typically for those with existing private insurance. Compounded GLP-1 products remain illegal in Canada.